Kailera Therapeutics, Inc. (KLRA)
D
Pipeline Grade
Financial Position (from SEC Filings)
$112.6M
Cash & Equivalents
$68.3M
Quarterly Burn Rate
5 mo
Est. Cash Runway
$2,679M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-05-01 | Phase2 Readout | — |
| 2027-07-07 | Phase2 Readout | — |
Active Clinical Trials (5)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07284875 | Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who ... | PHASE3 | Recruiting | 1,800 |
| NCT07284901 | Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes | PHASE3 | Recruiting | 1,700 |
| NCT07284979 | Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living Wi... | PHASE3 | Recruiting | 1,200 |
| NCT07497880 | Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Rela... | PHASE2 | Recruiting | 320 |
| NCT07458269 | Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes | PHASE2 | Recruiting | 250 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.